Actively Recruiting
Investigation of Copy Number Variations and Genetic Variants in POI
Led by Ospedale Policlinico San Martino · Updated on 2022-04-25
100
Participants Needed
1
Research Sites
987 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Primary ovarian insufficiency (POI), also known as premature ovarian failure, is an ovarian defect characterized by the premature (before the age of 40 years) depletion of ovarian follicles. POI affects about 1% of women, reaching 30% in some familial cases. This heterogeneous disorder is characterized by progressive cessation of the ovarian function with temporary or intermittent amenorrhea associated with elevated serum FSH concentration and low AMH dosage. Low serum AMH dosage is able to detect a diminished ovarian pool occurring before the onset of FSH elevation and the ultimate deficiency leading to amenorrhea. POI causes infertility and a poor ovarian response in IVF stimulations, and it has important health consequences for affected patients, including psychological distress, infertility, osteoporosis, autoimmune disorders, ischaemic heart disease. Although the cause of POI remains unknown in about 80% of the cases, several mechanisms have been proposed to explain ovarian dysfunction. Currently, a wide spectrum of causes has been linked to POI, including genetic, autoimmune, infectious, or iatrogenic ones. Genetic causes are highly heterogeneous and might explain at least some of the sporadic idiopathic cases, which comprise 50-90% of cases. Ten to fifteen percent of cases are X-linked abnormalities, mainly Turner Syndrome (45,X) or X structural abnormalities such as X deletions, X inversions, isochromosomes or X-autosome translocations. Also fragile X mental retardation 1 (FMR1) gene permutation (defined as having 55 to 200 CGG repeats in the 5' untranslated region of the gene) is another frequent genetic etiology. Irrespectively, the majority of cases remains idiopathic, and identifying precise causative genes for POI has been challenging.
CONDITIONS
Official Title
Investigation of Copy Number Variations and Genetic Variants in POI
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age at diagnosis less than 38 years
- Normal 46,XX karyotype without FMR1 premutation
- At least one ovarian reserve marker not age-appropriate: baseline FSH levels above cut-off and/or age-specific AMH below cut-off and/or antral follicle count less than 5
- Cancellation of a PMA cycle due to poor response (less than 3 follicles) to high-dose gonadotrophins (250 units daily) and/or
- Retrieval of fewer than 4 oocytes after high-dose stimulation (3000 units gonadotrophins)
You will not qualify if you...
- History of ovarian surgery
- Previous chemotherapy or radiotherapy
- Presence of endometriosis
- Known autoimmune diseases
- Known metabolic diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UOS Fisiopatologia della Riuproduzione Umana
Genova, Italy
Actively Recruiting
Research Team
P
Paola Scaruffi, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here